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Abstract
Background Itch is the most bothersome symptom reported by patients with psoriasis. Safe and effective treatments for
psoriasis that also address itch are needed.
Objectives To report effects of roflumilast cream on itch-related outcomes from a Phase 2b trial.
Methods Adults with chronic plaque psoriasis were randomized to roflumilast 0.3%, roflumilast 0.15%, or vehicle once-daily
for 12 weeks. Psoriasis severity was assessed via the Investigator Global Assessment (IGA; a 5-point scale assessing plaque
thickening, scaling, and erythema ranging from 0 [clear] to 4 [severe]) and ≥ 2 on a modified Psoriasis Area and Severity
Index (PASI-HD, which combines severity of lesions and area affected, ranging from 0 [no disease] to 72 [maximal disease],
with the actual percentage of the anatomical area involved in those patients with < 10% of anatomical area involved [e.g.,
0.1 for 1% to 0.9 for 9%]). Itch was evaluated via Worst Itch Numeric Rating Scale (WI-NRS), Psoriasis Symptom Diary
(PSD) Items 1 (severity of itch) and 2 (bother of itch), and itch-related sleep loss NRS scores. Post hoc correlation analyses
between WI-NRS and PASI, WI-NRS and itch-related sleep loss, and WI-NRS and DLQI were also performed.
Results Roflumilast-treated patients had significantly greater improvements than vehicle-treated patients in WI-NRS and
PSD Items 1 and 2 beginning at Week 2 and in itch-related sleep loss Weeks 6 through 12. Among patients with baseline
WI-NRS ≥ 6, significantly more patients achieved ≥ 4-point improvement with roflumilast than with vehicle as early as Week 2.
Itch severity had low correlation with PASI while WI-NRS and IGA were not always aligned.
Limitations The first assessment was at 2 weeks, limiting the ability to assess early onset of itch response.
Conclusion Roflumilast cream improved itch and itch-related sleep loss associated with chronic plaque psoriasis.
ClinicalTrials.gov identifier NCT03638258.

Key Points

1 Introduction

Itch is the most bothersome symptom of psoriasis and
contributes to disease severity.

Itch is an especially common and important symptom of
psoriasis [1–3]. Between 60 to 90% of patients with psoriasis
report pruritus, and many identify itch as their most troublesome symptom [1, 2, 4–9]. Although usually limited to
lesions, about 25% of patients experience generalized itching
in uninvolved skin [8]. Pruritus severity is not always correlated with severity of psoriasis [8, 9].
Itching can impair quality of life, increase feelings of agitation, embarrassment, and stigmatization, and contribute to
stress-related disorders, anxiety, and depression in patients
with psoriasis [1, 10]. Patients report itching affects concentration, physical activity, and work/school attendance, and
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50% report itching all or most of the time [2, 4]. Itch from
psoriasis can disrupt sleep, resulting in less sleep than usual
and difficulty in waking and feeling well-rested [1, 2]. Additionally, scratching may worsen psoriasis via koebnerization.
The mainstays of psoriasis treatment have varying efficacy in treating itch [1]. Current topical treatments for psoriasis have limitations, such as stinging and burning on sensitive locations with vitamin A or D derivatives and various
local side effects with long-term topical corticosteroids [11].
Safe and effective agents that treat psoriasis and the associated itch, particularly nonsteroidal treatment options, may
provide a more complete management strategy.
Phosphodiesterase-4 (PDE-4) is a proinflammatory
enzyme up-regulated in psoriatic skin compared with normal
skin [12]. Phosphodiesterase-4 inhibition reduces several
cytokines important in the pathogenesis of psoriasis, such
as tumor necrosis factor, interferon-γ, interleukin-17, and
interleukin-23 [13, 14]. Inhibition of PDE-4 reduces itching
in mouse models of dermatoses through mechanistic pathways independent of the anti-inflammatory action of PDE-4
[15–21]. The oral PDE-4 inhibitor apremilast (approved for
treatment of plaque psoriasis) and the topical PDE-4 inhibitor crisaborole (approved for treatment of mild to moderate atopic dermatitis) significantly improved itch in clinical
trials for psoriasis and atopic dermatitis, respectively [18,
20, 22, 23]. Roflumilast is a selective, highly potent PDE-4
inhibitor, with greater affinity for PDE-4 and approximately
25- to > 300-fold more potency than the other marketed oral
or topical PDE-4 inhibitors, apremilast and crisaborole, for
inhibiting in vitro cytokine secretion from human leukocytes
[13].
In a Phase 2b study evaluating efficacy and safety of oncedaily roflumilast cream (0.3% and 0.15%) for plaque psoriasis for 12 weeks, roflumilast resulted in significantly higher
percentages of patients with a score on the investigator
global assessment (IGA) indicating Clear or Almost Clear
status at 6 weeks versus vehicle (roflumilast 0.3%: 28%; roflumilast 0.15%: 23%; vehicle: 8%; p ≤ 0.004) [24]. Safety
of roflumilast was similar to vehicle with low incidence of
treatment-emergent adverse events, including application
site pain [24]. Here, we report results of patient-reported
outcomes (PROs) related to itch from that Phase 2b study.

2 Methods
2.1 Study Design
Full details about the methods, design, inclusion and exclusion criteria, and the primary efficacy and safety outcomes
for this parallel-group, double-blind, vehicle-controlled
Phase 2b clinical trial have been published previously [24].
The trial was conducted in accordance with the principles

of the Declaration of Helsinki and Good Clinical Practice
guidelines of the International Council for Harmonisation
and is registered on ClinicalTrials.gov (NCT03638258).
Before enrollment of patients, the study protocol and
informed consent form were reviewed and approved by an
appropriate Institutional Review Board or Independent Ethics Committee. All patients provided written informed consent before screening.
Patients were randomized to roflumilast 0.3% cream,
roflumilast 0.15% cream, or vehicle in a 1:1:1 ratio via a
computer-generated list. Roflumilast cream or vehicle was
applied once-daily to all psoriasis lesions for 12 weeks.
Palms and soles of the feet were treated but not included in
any measurements of efficacy.

2.2 Patients
Eligible patients were males and females aged ≥ 18 years
who had plaque psoriasis of at least mild severity affecting
2–20% body surface area (excluding the scalp, palms, and
soles). At screening, patients had to have a score ≥ 2 on the
IGA (a 5-point scale assessing plaque thickening, scaling,
and erythema ranging from 0 [clear] to 4 [severe]) and ≥ 2
on a modified Psoriasis Area and Severity Index (PASI-HD,
which combines severity of lesions and area affected, ranging from 0 [no disease] to 72 [maximal disease], with the
actual percentage of the anatomical area involved in those
patients with < 10% of anatomical area involved [e.g., 0.1
for 1% to 0.9 for 9%]) [25].
Key exclusion criteria were excessive exposure of treated
areas to natural or artificial sunlight, tanning bed, or other
light emitting device; diagnosis of guttate, erythrodermic/
exfoliative, palmoplantar involvement only, or pustular psoriasis; and use of oral roflumilast or other PDE-4 inhibitors
within the previous 4 weeks.

2.3 Study Assessments
The PASI-HD assessment was performed to assess severity of psoriasis at screening; baseline; and Weeks 2, 4, 6,
8, and 12. Itch was assessed using the secondary efficacy
endpoints of Worst Itch Numeric Rating Scale (WI-NRS)
[26], Items 1 and 2 of the Psoriasis Symptom Diary (PSD),
and Itch-Related Sleep Loss Numeric Rating Scale (NRS).
The WI-NRS was determined by asking patients to assess
their worst itch over the past 24 h on a scale of 0 (no itch)
to 10 (worst imaginable itch) [27]. In those patients with a
WI-NRS ≥ 6 at baseline, the percentage of those achieving
a 4-point reduction in WI-NRS was also determined. The
PSD is a 16-item (24-h recall) assessment that measures
burden and severity of psoriasis signs and symptoms and
impact on functional health [28, 29]. Item 1 of the PSD
was “Overall, how severe was your psoriasis-related itching
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over the past 24 h?” and patients reported on a scale of 0
(no itching) to 10 (itching as bad as you can imagine) [28,
29]. Patients responded to Item 2 of the PSD by answering
“Overall, how bothered were you by your psoriasis-related
itching over the past 24 h?” on a scale of 0 (not bothered
at all) to 10 (bothered as bad as you can imagine) [28, 29].
Itch-related sleep loss was evaluated on a scale from 0 (no
itch-related sleep loss) to 10 (itch-related sleep loss as bad
as it could be) over the previous 24 h. The Dermatology Life
Quality Index (DLQI) is a simple 10-item questionnaire used
to assess the psychosocial impact of dermatology diseases
[30]. Itch-related assessments were performed at baseline
and Weeks 2, 4, 6, 8, and 12. The DLQI was added as an
amendment to the protocol; therefore, DLQI was evaluated
only in a subset of patients.

2.4 Statistical Analysis
All statistical tests were two-sided at the 0.05 level of significance with no adjustment for multiple comparison.
Efficacy analyses were performed on the intention-to-treat
population. Achievement of a 4-point reduction in WI-NRS
in patients with baseline WI-NRS ≥ 6 was analyzed with
logistic regression with a factor of treatment group and the
respective baseline score as a covariate. The other continuous endpoints were analyzed with an analysis of covariance
with a factor of treatment group and respective baseline
score as a covariate. The primary method of handling missing efficacy data was a mixture of linear interpolation and
last observation carried forward (if the missing assessment
was not followed by at least one observed assessment).
A post hoc analysis was performed to determine correlation between WI-NRS and PASI, WI-NRS and itch-related
sleep loss, and WI-NRS and DLQI. Pearson correlation coefficients were calculated for these measures at baseline.

3 Results
3.1 Patients
A total of 331 patients were randomized to and received
roflumilast 0.3% cream (n = 109 patients), roflumilast 0.15%
cream (n = 113 patients), or vehicle (n = 109 patients). Baseline demographic characteristics were similar among groups
(Table 1). Patient ages ranged from 18 to 89 years (mean:
53.9 years).

3.2 Study Assessments
The overall baseline mean PASI score was 7.8 (Table 1). The
percentage reduction from baseline for PASI was greater in
roflumilast-treated groups than in the vehicle-treated group

from Week 2 to Week 12 (all p < 0.001). Overall baseline
mean scores for WI-NRS were similar across groups at 5.9
(Table 1). Patients in both roflumilast-treated groups had
similar improvements in WI-NRS score. The least squares
mean decrease (improvement) from baseline was greater for
patients treated with roflumilast than for those treated with
vehicle beginning at Week 2 (p ≤ 0.002; Fig. 1). Among the
subgroup of patients with baseline WI-NRS ≥ 6, a significantly greater percentage of patients treated with roflumilast
0.3% achieved an improvement ≥ 4 points than among those
treated with vehicle by the first timepoint measured, Week
2 (p ≤ 0.034; Fig. 2). For patients treated with roflumilast
0.15%, the percentage who achieved this level of improvement was greater than for those treated with vehicle at Week
6 (p = 0.012) and Week 12 (p < 0.001).
For PSD, mean baseline scores for Item 1 (severity of
itch) were similar across treatment groups (roflumilast 0.3%:
5.5; roflumilast 0.15%: 5.3; vehicle: 5.5; Table 1). Mean
improvement was greater for patients treated with roflumilast than for those treated with vehicle at Weeks 2 to 12
(p ≤ 0.012; Fig. 3). Mean baseline scores for PSD Item 2
(bother of itch) were also similar across treatment groups
(roflumilast 0.3%: 5.2; roflumilast 0.15%: 5.2; vehicle: 5.5;
Table 1) and mean decrease from baseline was greater for
patients treated with roflumilast than for those treated with
vehicle Weeks 2 to 12 (p ≤ 0.010; Fig. 3).
The overall baseline mean score for itch-related sleep
loss was 3.1 and was similar across groups (Table 1). Both
active treatment groups had similar improvements in itchrelated sleep loss, and this was greater for patients treated
with roflumilast at either dose than for those treated with
vehicle beginning at Week 6 (p ≤ 0.022; Fig. 4). Overall
baseline mean DLQI score was 8.0 (Table 1). The response
for patient-reported quality of life (DLQI) was consistent
with those observed on itch-related sleep loss with improvement observed at Week 6 for patients treated with roflumilast
0.3% (p = 0.045). At Week 12, the improvement in DLQI
score (3.0 in patients treated with roflumilast 0.3% and 3.9
in patients treated with roflumilast 0.15%) was greater than
in patients in the vehicle-treated group (1.2; p ≤ 0.036).

3.3 Post Hoc Correlation Analyses
At baseline, WI-NRS and PASI were positively correlated
in all treatment groups, although these correlations were
low. Pearson’s correlation coefficients were 0.189 for roflumilast 0.3%, 0.282 for roflumilast 0.15%, and 0.205 for
vehicle (p ≤ 0.05 for all correlations). At Week 12, Pearson’s correlation coefficients were 0.399 for roflumilast
0.3%, 0.334 for roflumilast 0.15%, and 0.558 for vehicle
(p ≤ 0.05 for all correlations; Fig. 5). Similarly, patientreported itch (WI-NRS) and physician-assessed disease
severity (IGA) were not always aligned. At baseline,
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Table 1  Baseline characteristics (intention-to-treat population)

Age, mean (SD), years
Sex, n (%)
Male
Female
Race, n (%)
White
Black
Multiple/other
IGA scorea
2 (mild), n (%)
3 (moderate), n (%)
4 (severe), n (%)
Body surface area affected by psoriasis, mean (SD), %
PASIb, mean score (SD)
WI-NRSc, mean score (SD)
WI-NRS score ≥ 6, n (%)
PSD Item 1 c, itch severity, mean (SD)
PSD Item 2 c, itch burden, mean (SD)
Itch-related sleep lossc, mean (SD)
DLQI, mean (SD)d

Roflumilast 0.3%
(n = 109)

Roflumilast 0.15%
(n = 113)

Vehicle
(n = 109)

51.7 (14.1)

54.4 (14.2)

55.5 (13.5)

56 (51.4)
53 (48.6)

62 (54.9)
51 (45.1)

67 (61.5)
42 (38.5)

82 (75.2)
12 (11.0)
15 (13.8)

95 (84.1)
10 (8.8)
8 (7.1)

92 (84.4)
7 (6.4)
10 (9.2)

17 (15.6)
84 (77.1)
8 (7.3)
6.3 (4.0)
7.7 (3.6)
6.1 (2.7)
71 (65.1)
5.5 (2.8)
5.2 (3.0)
2.9 (3.2)
6.7 (5.5) n = 58

18 (15.9)
83 (73.5)
12 (10.6)
6.4 (3.9)
8.0 (3.9)
5.6 (3.1)
62 (54.9)
5.3 (3.1)
5.2 (3.3)
3.0 (3.2)
8.8 (7.2) n = 60

11 (10.1)
89 (81.7)
9 (8.3)
6.4 (3.6)
7.6 (3.1)
5.9 (2.9)
64 (58.7)
5.5 (3.0)
5.5 (3.2)
3.4 (3.2)
8.5 (5.6) n = 62

DLQI Dermatology Life Quality Index, IGA investigator global assessment, PASI Psoriasis Area and Severity Index, PSD Psoriasis Symptom
Diary, SD standard deviation, WI-NRS Worst Itch Numeric Rating Scale
a

b
c
d

Scale of clear (0) to severe (4)
Scale of 0 (no disease) to 72 (maximal disease)
Scale of 0 (none) to 10 (worst)
Added to study as a protocol amendment and evaluated only in a subset of patients

Fig. 1  Least squares mean change in WI-NRS score over time (intention-to-treat population). Assessed on a scale from 0 (no itch) to 10
(worst imaginable itch). Missing data imputed using linear interpolation and last observation carried forward where linear interpola-

tion was not computationally possible. CI confidence interval, LS
least squares, WI-NRS Worst Itch Numeric Rating Scale. *Nominal
p < 0.05 vs vehicle
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Fig. 2  Proportion of patients with WI-NRS score ≥ 6 at baseline who
achieved a ≥ 4-point reduction from baseline. Assessed as the worst
itch over the past 24 h on a scale ranging from 0 (no itch) to 10 (worst
imaginable itch). Data are presented for intention-to-treat population.

Missing data imputed using linear interpolation and last observation
carried forward where linear interpolation was not computationally
possible. CI confidence interval, WI-NRS Worst Itch Numeric Rating
Scale. *Nominal p < 0.05 vs vehicle

Fig. 3  Least squares mean change in severity of itch (left panel)
and bother of itch (right panel) over time (intention-to-treat population). Assessed on scales from 0 (no itch/not bothered at all) to 10
(itching/bothered as bad as you can imagine). Missing data imputed

using linear interpolation and last observation carried forward where
linear interpolation was not computationally possible. CI confidence
interval, LS least squares, PSD Psoriasis Symptom Diary. *Nominal
p < 0.05 vs vehicle

patients with low itch scores included those with moderate
or severe disease, as measured by IGA, whereas patients
with mild disease (IGA = 1 to 2) often reported considerable itch (WI-NRS ≥ 5). Worst Itch Numeric Rating Scale
and itch-related sleep loss were positively correlated in
all treatment groups. Pearson’s correlations were 0.548
for roflumilast 0.3%, 0.646 for roflumilast 0.15%, and
0.652 for vehicle (p < 0.001 for all). This pattern was also
observed for correlations between WI-NRS and DLQI with
positive correlations seen at baseline and Pearson’s correlations of 0.445, 0.617, and 0.422 for roflumilast 0.3%,
roflumilast 0.15%, and vehicle, respectively (p < 0.001 for
all).

4 Discussion
Evaluating PROs in clinical trials provides information
about the impact psoriasis symptoms have on patients’
lives and can support regulatory approval and labeling [2].
Itch associated with psoriasis is one of the most important
and bothersome symptoms as reported by patients with
psoriasis [2]. Several PROs related to itch were assessed
in this study. Patients treated with roflumilast had greater
improvements in WI-NRS as well as severity and bother
of itch (as measured by PSD) compared with those treated
with vehicle. These improvements occurred by the first
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Fig. 4  Least squares mean change in itch-related sleep loss over time
(intention-to-treat population). Assessed on a scale from 0 (no itchrelated sleep loss) to 10 (itch-related sleep loss as bad as it could be).
Missing data imputed using linear interpolation and last observation

carried forward where linear interpolation was not computationally
possible. CI confidence interval, IRSL itch-related sleep loss, LS least
squares. *Nominal p < 0.05 vs vehicle

Fig. 5  Changes from baseline on WI-NRS and PASI for individual
patients treated with roflumilast cream 0.3% (left panel), roflumilast
cream 0.15% (middle panel), or vehicle cream (right panel) for 12

weeks. PASI Psoriasis Area and Severity Index, WI-NRS Worst Itch
Numeric Rating Scale

timepoint measured, Week 2, with further improvements
occurring over the course of the study.
Recognizing that a statistical improvement in the WINRS scale may not necessarily mean the patient experienced a clinically meaningful improvement, we also
evaluated the proportion of patients with at least a 4-point
change in WI-NRS, which is considered a clinically and
qualitatively meaningful improvement in itch among
patients with moderate to severe plaque psoriasis [26].
In this study, among patients with baseline WI-NRS ≥ 6,
more roflumilast-treated patients had an improvement ≥ 4
points than among vehicle-treated patients with a greater

percentage of patients treated with roflumilast 0.3% found
at the first timepoint evaluated, Week 2.
Itching or scratching associated with psoriasis severely
impacts a patient’s sleep by affecting their ability to fall
asleep and/or stay asleep [2, 31]. Patients with psoriasis
report more impairments in sleep quality, latency, duration, and efficiency, experience more sleep disturbances,
and use sleeping medications more than individuals without psoriasis [31, 32]. Impairment of sleep quality and
duration, including difficulty sleeping due to itching or
scratching, is associated with negative effects on quality
of life among patients with psoriasis [2, 31]. A mediation
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modeling analysis of several studies shows that itch is the
driving force in DLQI improvement in psoriasis [33]. In
the current study, roflumilast cream reduced (improved)
itch-related sleep loss and improved patient-reported quality of life (DLQI) compared with vehicle.
In the post hoc correlation analysis, WI-NRS was positively correlated with PASI, itch-related sleep loss, and
DLQI at baseline; however, the correlation with PASI was
low. Additionally, at baseline, IGA and WI-NRS were
not always aligned, with some patients with mild disease
experiencing considerable itch. These results are similar
to other studies in which itch intensity was not or only
weakly correlated with psoriasis severity but was correlated with sleep and quality of life [1, 7–9, 34]. Thus,
patients may have considerable itch despite mild psoriasis
and this suggests itch related to psoriasis is caused by multiple factors, including mediators from the nervous, endocrine, and immune systems that induce or aggravate itch
in response to external stimuli and psychological stress in
addition to inflammation of psoriatic lesions [35].
One limitation of this analysis was that the earliest
timepoint at which efficacy was evaluated was Week 2
and any changes in itch prior to this timepoint were not
captured. In addition, no adjustments for multiple comparisons or multiplicity were made for these secondary
endpoints. These outcomes are reported as point estimates
and unadjusted 95% confidence intervals without multiplicity adjustment. Next, DLQI was added as a protocol
amendment, which resulted in DLQI being evaluated in
only a subset of patients rather than the entire study population. Fourth, itch-related sleep loss was evaluated on a
numeric rating scale only and not more extensive measures
of insomnia or sleep quality such as the Athens Insomnia
Scale or Pittsburgh Sleep Quality Index.
In conclusion, in this Phase 2b study, once-daily roflumilast cream significantly improved itch and itch-related sleep
loss in patients with chronic plaque psoriasis. This suggests
this potent PDE-4 inhibitor may be an effective topical treatment of these important symptoms associated with chronic
plaque psoriasis.
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